The revenue of the dermatological drugs market in 2018 is estimated at $31bn and is expected to grow at a CAGR of 3.7% in the first half of the forecast period. Psoriasis drugs segment accounted for the largest share of the market in 2018, this segment accounted for 38% of the global dermatological drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 355-page report you will receive 133 tables and 154 figures– all unavailable elsewhere. The 355-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
  • Dermatological drugs market forecasts from 2020-2030
  • This report also breaks down the revenue forecast for the main submarkets:
  • Psoriasis
  • Skin Infections
  • Acne
  • Dermatitis
Analysis of the Psoriasis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
  • Humira
  • Stelara
  • Enbrel
  • Remicade
  • Taltz
  • Otezla
  • Cosentyx
Analysis of the Skin Infections drugs market. Revenue forecasts to 2030 are provided for the following drugs:
  • Cubicin
  • Zyvox
  • Valtrex
  • Canesten
  • Lamisil
  • Bactroban
 Analysis of the Acne drugs market. Revenue forecasts to 2030 are provided for the following drugs:
  • Solodyn
  • Epiduo
  • Claravis
  • Aczone
  • Differin
  • Abscorical/Epirus
  • Ziana
  • Doryx
Analysis of the Dermatitis drugs market. Revenue forecasts to 2030 are provided for the following drugs:
  • Bepanthen/Bepanthol
  • Protopic
  • Dermovate
  • Elocon
This report provides individual revenue forecasts to 2030 for these regional and national markets:
  • North America: US & Canada
  • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
  • Asia-Pacific: China, Japan, India, Rest of Asia-Pacific
  • Latin America: Brazil, Mexico, Rest of Latin America
  • Middle East & Africa (MEA): Saudi Arabia, South Africa, Rest of MEA
  • Each regional market is further segmented by indication: psoriasis, skin infection, acne, dermatitis and others.
  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
  • Our study includes SWOT analysis and Porter’s Five Force analysis of the dermatological drugs market.
Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
  • AbbVie
  • Allergan
  • Amgen
  • Bausch Health
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly
  • Galderma (Nestle Skin Health S.A.)
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • LEO Pharma
  • Merck & Co, Inc.
  • Novartis
  • Pfizer
Key questions answered by this report:
  • How is the dermatological drugs market evolving?
  • What is driving and restraining the dermatological drugs market?
  • What are the market shares of each segment of the overall dermatological drugs market in 2019?
  • How will each dermatological drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each dermatological drugs submarket develop from 2020 to 2030?
  • Which individual therapies will prevail and how will these shifts be responded to?
  • What will be the main driver for the overall market from 2020 to 2030?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • Will leading national dermatological drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry evolve during the period between 2019 and 2030?